ARTL — Artelo Biosciences Share News
0.000.00%
Last trade - 00:00NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Artelo Biosciences Announces Reverse Stock Split
Artelo Biosciences Q3 net loss widens to $3.1 mln
Brief: Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, Cpa, As Chief Financial Officer
Brief: Artelo Biosciences enters cooperation letter agreement with Daniel S. Farb - SEC filing
Brief: Artelo Biosciences Announces Closing Of $3.0 Million Public Offering
Brief: Artelo Biosciences Announces Pricing Of $3.0 Million Public Offering
Brief: Artelo Biosciences Announces Proposed Underwritten Public Offering
Brief: Artelo Biosciences Announces Positive Interim Phase 2 Cares Results For The Treatment Of Cancer Anorexia-Cachexia Syndrome (Cacs)
U.S. STOCKS ON THE MOVE-Artelo Biosciences, Coya, Vital Energy
U.S. STOCKS ON THE MOVE-Artelo Biosciences, Coya, Vital Energy
Brief: Artelo Biosciences Announces New Data From An Initial Food Effect Investigation With ART26.12
Artelo Biosciences climbs on prelim pain drug trial data
Brief: Artelo Biosciences Terminates Securities Purchase Agreement
Artelo Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Artelo Biosciences Receives Favorable Uk Mhra Guidance For A Phase 1 Trial Of Art12.11, The Company’S Proprietary CbdTmp Cocrystal Being Developed For The Treatment Of Anxiety And Depression
Brief: Artelo Biosciences - Enters ATM Offering Agreement With R.F. Lafferty - SEC Filing
Brief: Artelo Biosciences Announces Positive First-In-Human Data For ART26.12, A Novel Non-Opioid Treatment Candidate For Persistent Pain
Brief: Artelo Biosciences Inc - Regains Nasdaq Minimum Bid Price Compliance